The AGITG’s Translational Research (TR) Program aims to add value to important clinical trials in GI cancer by supporting the collection and use of biospecimens for future research. For example, these valuable samples can be used by researchers to find biomarkers that are associated with good response to drugs used in AGITG trials, and, if response is not as good as expected, to find out why.
Translational research is a feature of many of our trials – over thirty AGITG clinical trials collect or have collected various biological samples from patients. More than 80% of our trials have led to translational research studies. Our TR Program assists us to develop translational research in GI cancers by providing access to stored biological specimens acquired from AGITG trials.
→ Find out what TR samples are available for access and learn more about the process to access AGITG biospecimens.
→ There are expenses associated with accessing the AGITG GI Cancer Biobank – learn why cost recovery is necessary and understand the costs involved.
Our TR Program is directed by the AGITG Translational Research Committee (TRC), comprised of a panel of experts whose specialties include biological research, medical oncology, surgery and pathology, and consumer representation.
The AGITG endorses reviewed concepts which can assist in progressing the work by facilitating access to funding opportunities, promotion of the research through AGITG channels and assistance with external grant applications. We encourage investigators to bring their research concepts to the TRC for concept refinement prior to request for endorsement by the AGITG.
Concepts that address the AGITG research priorities are particularly encouraged; however, all concepts addressing research questions in GI cancer are considered. We also partner with industry and collaborative organisations to further develop our research.
- Biospecimen and Data Sharing Policy
- AGITG Publication Policy
- AGITG Cost Recovery Guidelines
- AGITG Sample Access Application Form (to be completed upon initial approval from Study Chair and Translational Research Committee)
For any other inquiries, please contact Dr Sarah Hayes, AGITG Translational Research Coordinator.
T: +61 2 7208 2706